Chemistry:LY2181308
From HandWiki
LY2181308 is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.[1]
It being investigated for a number of different cancers.[2]
It is targeted at survivin which prevents cells dying.[3]
Clinical trials
It has completed a phase II trial for acute myeloid leukemia.[4]
A phase II trial for non-small cell lung cancer has started.[5]
A phase II trial for hormone-refractory prostate cancer will run until early 2012.[6]
References
- ↑ "Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors.". Cancer Chemother. Pharmacol. 68 (2): 505–11. Nov 2010. doi:10.1007/s00280-010-1506-7. PMID 21079959.
- ↑ http://clinicaltrials.gov/ct2/results?term=LY2181308
- ↑ http://www.isispharm.com/Pipeline/Therapeutic-Areas/Cancer.htm#LY2181308
- ↑ A phase II Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- ↑ A Phase II Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
- ↑ A Phase II Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer
 |
